Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Evans-Axelsson

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
American Journal of Nuclear Medicine and Molecular Imaging|July 2, 2014
Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancerSusan Evans-Axelsson, Oskar Vilhelmsson Timmermand, Charlotte Welinder, et al.
Nuclear Medicine and Biology|January 12, 2015
Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distributionOskar Vilhelmsson-Timmermand, Elmer Santos, Daniel L J Thorek, et al.
International Journal of Surgery Protocols|June 10, 2024
Research protocol for an observational health data analysis to assess the applicability of randomized controlled trials focusing on newly diagnosed metastatic prostate cancer using real-world data: PIONEER IMI's "big data for better outcomes" programGiorgio Gandaglia, Francesco Pellegrino, Bertrand De Meulder, et al.
Clinical Genitourinary Cancer|October 15, 2022
How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-AnalysisAino Siltari, Ragnar Lönnerbro, Karl Pang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 27, 2017
Establishing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerWolfgang P Fendler, Andreea D Stuparu, Susan Evans-Axelsson, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 12, 2012
Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen aloneSusan Evans-Axelsson, David Ulmert, Anders Örbom, et al.
Nuclear Medicine and Biology|May 11, 2018
Microscale radiosynthesis, preclinical imaging and dosimetry study of [<sup>18</sup>F]AMBF<sub>3</sub>-TATE: A potential PET tracer for clinical imaging of somatostatin receptorsKsenia Lisova, Maxim Sergeev, Susan Evans-Axelsson, et al.
EJNMMI Research|October 31, 2018
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancerKatharina Lückerath, Liu Wei, Wolfgang P Fendler, et al.
Central European Journal of Urology|March 21, 2025
Baseline characteristics and clinical outcomes of prostate cancer patients on delayed palliative management: a PIONEER analysis based on big dataLana Yh Lai, Vasileios Sakalis, Christos Chatzichristos, et al.
Nature Reviews. Urology|April 3, 2023
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortiumMuhammad Imran Omar, Steven MacLennan, Maria J Ribal, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Nuclear Medicine and Molecular Imaging|July 2, 2014
Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancerSusan Evans-Axelsson, Oskar Vilhelmsson Timmermand, Charlotte Welinder, et al.
Nuclear Medicine and Biology|January 12, 2015
Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distributionOskar Vilhelmsson-Timmermand, Elmer Santos, Daniel L J Thorek, et al.
International Journal of Surgery Protocols|June 10, 2024
Research protocol for an observational health data analysis to assess the applicability of randomized controlled trials focusing on newly diagnosed metastatic prostate cancer using real-world data: PIONEER IMI's "big data for better outcomes" programGiorgio Gandaglia, Francesco Pellegrino, Bertrand De Meulder, et al.
Clinical Genitourinary Cancer|October 15, 2022
How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-AnalysisAino Siltari, Ragnar Lönnerbro, Karl Pang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 27, 2017
Establishing <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerWolfgang P Fendler, Andreea D Stuparu, Susan Evans-Axelsson, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 12, 2012
Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen aloneSusan Evans-Axelsson, David Ulmert, Anders Örbom, et al.
Nuclear Medicine and Biology|May 11, 2018
Microscale radiosynthesis, preclinical imaging and dosimetry study of [<sup>18</sup>F]AMBF<sub>3</sub>-TATE: A potential PET tracer for clinical imaging of somatostatin receptorsKsenia Lisova, Maxim Sergeev, Susan Evans-Axelsson, et al.
EJNMMI Research|October 31, 2018
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancerKatharina Lückerath, Liu Wei, Wolfgang P Fendler, et al.
Central European Journal of Urology|March 21, 2025
Baseline characteristics and clinical outcomes of prostate cancer patients on delayed palliative management: a PIONEER analysis based on big dataLana Yh Lai, Vasileios Sakalis, Christos Chatzichristos, et al.
Nature Reviews. Urology|April 3, 2023
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortiumMuhammad Imran Omar, Steven MacLennan, Maria J Ribal, et al.
Pageof 4